Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × LY3023414 × 1 year × Clear all

Status

Sponsor Class

Study Type

Interventional 4 Expanded_access 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Interventions

3-Iodobenzylguanidine 2 Gemcitabine 2 Powders 2 Suspensions 2 ruxolitinib 2 Abiraterone Acetate 1 Amifampridine 1 Androgen Antagonists 1 Asparaginase 1 Bone Marrow Transplantation 1 Capecitabine 1 Cyclophosphamide 1 Docetaxel 1 Eflornithine 1 Everolimus 1 FANG vaccine 1 HMPL-013 1 Hydrocortisone 1 Immunotherapy, Adoptive 1 Insulin Infusion Systems 1 LY3023414 1 Magnetic Resonance Spectroscopy 1 Methionine 1 Nivolumab 1 Paclitaxel 1 Peripheral Blood Stem Cell Transplantation 1 Prednisolone 1 Prednisone 1 Proton Pump Inhibitors 1 Standard of Care 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02632994 2025-09-29

Master Rollover Protocol for Continued Safety Assessment of Study Drug

Eli Lilly and Company

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡